HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma.

Abstract
Seven hundred sixty-one patients with operable differentiated thyroid carcinoma were treated between 1931 and 1970. Median follow-up time was 18 years and ranged from 5 to 40 years. Sixty-three percent of the patients were followed more than 15 years, and 46% were followed more than 20 years. Because resections usually spared sufficient thyroid tissue for homeostasis, thyroid hormone was not routinely prescribed after operations performed before 1960. Altogether 244 patients with papillary carcinoma and 76 patients with follicular carcinoma received thyroid hormone, while 296 patients with papillary carcinoma and 45 patients with follicular carcinoma did not receive thyroid hormone after operation. With papillary carcinoma, 14% of men greater than 40 and women greater than 50 years of age (high risk) but only 2% of men less than or equal to 40 years of age and women less than or equal to 50 years of age (low risk) died of disease (P 0.0001). Twenty-six percent of high-risk but only 4% of patients with low-risk follicular cancer died (P 0.0001). However, there was no statistically significant improvement in survival times with use of thyroid hormone when patients were categorized by risk group and pathology. These data support the importance of age and sex in previously described risk groups; these factors supersede the effects of adjuvant treatment. This absence of effect on survival times calls into question current recommendations for routine use of thyroid hormone after surgical therapy. Conceptually, such absence of adjunctive hormone effect on survival time after operation is similar to hormonal effects in other endocrine cancers, which may nevertheless provide good palliation in some cases.
AuthorsB Cady, K Cohn, R L Rossi, C E Sedgwick, W A Meissner, J Werber, R S Gelman
JournalSurgery (Surgery) Vol. 94 Issue 6 Pg. 978-83 (Dec 1983) ISSN: 0039-6060 [Print] United States
PMID6648813 (Publication Type: Journal Article)
Chemical References
  • Thyroxine
Topics
  • Adenocarcinoma (drug therapy, mortality, surgery)
  • Adult
  • Carcinoma, Papillary (drug therapy, mortality, surgery)
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Thyroid Neoplasms (drug therapy, mortality, surgery)
  • Thyroxine (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: